167 related articles for article (PubMed ID: 29504187)
1. Clinical testing of three novel transient receptor potential cation channel subfamily V member 1 antagonists in a pharmacodynamic intradermal capsaicin model.
Sjögren E; Kullenberg T; Jonzon B; Segerdahl M; Stålberg O; Halldin MM; Sundgren-Andersson AK
Eur J Pain; 2018 Aug; 22(7):1214-1228. PubMed ID: 29504187
[TBL] [Abstract][Full Text] [Related]
2. The effect of intradermal microdosing of a transient receptor potential cation channel subfamily V member 1 antagonist on heat evoked pain and thermal thresholds in normal and ultraviolet-C exposed skin in healthy volunteers.
Sjögren E; Ståhle L; Quiding H; Jonzon B; Halldin MM; Sundgren AK
Eur J Pain; 2019 Nov; 23(10):1767-1779. PubMed ID: 31314954
[TBL] [Abstract][Full Text] [Related]
3. Preclinical characterization of three transient receptor potential vanilloid receptor 1 antagonists for early use in human intradermal microdose analgesic studies.
Sjögren E; Halldin MM; Stålberg O; Sundgren-Andersson AK
Eur J Pain; 2018 May; 22(5):889-903. PubMed ID: 29377430
[TBL] [Abstract][Full Text] [Related]
4. Characterizing the PK/PD relationship for inhibition of capsaicin-induced dermal vasodilatation by MK-3207, an oral calcitonin gene related peptide receptor antagonist.
Li CC; Vermeersch S; Denney WS; Kennedy WP; Palcza J; Gipson A; Han TH; Blanchard R; De Lepeleire I; Depré M; Murphy MG; Van Dyck K; de Hoon JN
Br J Clin Pharmacol; 2015 May; 79(5):831-7. PubMed ID: 25377933
[TBL] [Abstract][Full Text] [Related]
5. TRPA1 and TRPV1 Antagonists Do Not Inhibit Human Acidosis-Induced Pain.
Schwarz MG; Namer B; Reeh PW; Fischer MJM
J Pain; 2017 May; 18(5):526-534. PubMed ID: 28062311
[TBL] [Abstract][Full Text] [Related]
6. Capsaicin, Nociception and Pain.
Frias B; Merighi A
Molecules; 2016 Jun; 21(6):. PubMed ID: 27322240
[TBL] [Abstract][Full Text] [Related]
7. LASSBio-881: an N-acylhydrazone transient receptor potential vanilloid subfamily type 1 antagonist orally effective against the hypernociception induced by capsaicin or partial sciatic ligation.
Tributino JL; Santos ML; Mesquita CM; Lima CK; Silva LL; Maia RC; Duarte CD; Barreiro EJ; Fraga CA; Castro NG; Miranda AL; Guimaraes MZ
Br J Pharmacol; 2010 Apr; 159(8):1716-23. PubMed ID: 20401963
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, positive-controlled, 3-way cross-over human experimental pain study of a TRPV1 antagonist (V116517) in healthy volunteers and comparison with preclinical profile.
Arendt-Nielsen L; Harris S; Whiteside GT; Hummel M; Knappenberger T; O'Keefe S; Kapil R; Kyle D
Pain; 2016 Sep; 157(9):2057-2067. PubMed ID: 27168361
[TBL] [Abstract][Full Text] [Related]
9. The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans.
Chizh BA; O'Donnell MB; Napolitano A; Wang J; Brooke AC; Aylott MC; Bullman JN; Gray EJ; Lai RY; Williams PM; Appleby JM
Pain; 2007 Nov; 132(1-2):132-41. PubMed ID: 17659837
[TBL] [Abstract][Full Text] [Related]
10. Histamine Receptor H1-Mediated Sensitization of TRPV1 Mediates Visceral Hypersensitivity and Symptoms in Patients With Irritable Bowel Syndrome.
Wouters MM; Balemans D; Van Wanrooy S; Dooley J; Cibert-Goton V; Alpizar YA; Valdez-Morales EE; Nasser Y; Van Veldhoven PP; Vanbrabant W; Van der Merwe S; Mols R; Ghesquière B; Cirillo C; Kortekaas I; Carmeliet P; Peetermans WE; Vermeire S; Rutgeerts P; Augustijns P; Hellings PW; Belmans A; Vanner S; Bulmer DC; Talavera K; Vanden Berghe P; Liston A; Boeckxstaens GE
Gastroenterology; 2016 Apr; 150(4):875-87.e9. PubMed ID: 26752109
[TBL] [Abstract][Full Text] [Related]
11. Design and characterization of a noncompetitive antagonist of the transient receptor potential vanilloid subunit 1 channel with in vivo analgesic and anti-inflammatory activity.
García-Martínez C; Fernández-Carvajal A; Valenzuela B; Gomis A; Van Den Nest W; Ferroni S; Carreño C; Belmonte C; Ferrer-Montiel A
J Pain; 2006 Oct; 7(10):735-46. PubMed ID: 17018334
[TBL] [Abstract][Full Text] [Related]
12. Safety, Pharmacokinetics, and Pharmacodynamics Study in Healthy Subjects of Oral NEO6860, a Modality Selective Transient Receptor Potential Vanilloid Subtype 1 Antagonist.
Brown W; Leff RL; Griffin A; Hossack S; Aubray R; Walker P; Chiche DA
J Pain; 2017 Jun; 18(6):726-738. PubMed ID: 28188907
[TBL] [Abstract][Full Text] [Related]
13. Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockade.
Gavva NR; Bannon AW; Hovland DN; Lehto SG; Klionsky L; Surapaneni S; Immke DC; Henley C; Arik L; Bak A; Davis J; Ernst N; Hever G; Kuang R; Shi L; Tamir R; Wang J; Wang W; Zajic G; Zhu D; Norman MH; Louis JC; Magal E; Treanor JJ
J Pharmacol Exp Ther; 2007 Oct; 323(1):128-37. PubMed ID: 17652633
[TBL] [Abstract][Full Text] [Related]
14. Pharmacology of modality-specific transient receptor potential vanilloid-1 antagonists that do not alter body temperature.
Reilly RM; McDonald HA; Puttfarcken PS; Joshi SK; Lewis L; Pai M; Franklin PH; Segreti JA; Neelands TR; Han P; Chen J; Mantyh PW; Ghilardi JR; Turner TM; Voight EA; Daanen JF; Schmidt RG; Gomtsyan A; Kort ME; Faltynek CR; Kym PR
J Pharmacol Exp Ther; 2012 Aug; 342(2):416-28. PubMed ID: 22570364
[TBL] [Abstract][Full Text] [Related]
15. Amelioration of neuropathic pain by novel transient receptor potential vanilloid 1 antagonist AS1928370 in rats without hyperthermic effect.
Watabiki T; Kiso T; Kuramochi T; Yonezawa K; Tsuji N; Kohara A; Kakimoto S; Aoki T; Matsuoka N
J Pharmacol Exp Ther; 2011 Mar; 336(3):743-50. PubMed ID: 21098091
[TBL] [Abstract][Full Text] [Related]
16. A randomised trial evaluating the effects of the TRPV1 antagonist SB705498 on pruritus induced by histamine, and cowhage challenge in healthy volunteers.
Gibson RA; Robertson J; Mistry H; McCallum S; Fernando D; Wyres M; Yosipovitch G
PLoS One; 2014; 9(7):e100610. PubMed ID: 25047038
[TBL] [Abstract][Full Text] [Related]
17. Antinociceptive activity of transient receptor potential channel TRPV1, TRPA1, and TRPM8 antagonists in neurogenic and neuropathic pain models in mice.
Sałat K; Filipek B
J Zhejiang Univ Sci B; 2015 Mar; 16(3):167-78. PubMed ID: 25743118
[TBL] [Abstract][Full Text] [Related]
18. Capsaicin (TRPV1 Agonist) therapy for pain relief: farewell or revival?
Knotkova H; Pappagallo M; Szallasi A
Clin J Pain; 2008 Feb; 24(2):142-54. PubMed ID: 18209521
[TBL] [Abstract][Full Text] [Related]
19. Eriodictyol: a flavonoid antagonist of the TRPV1 receptor with antioxidant activity.
Rossato MF; Trevisan G; Walker CI; Klafke JZ; de Oliveira AP; Villarinho JG; Zanon RB; Royes LF; Athayde ML; Gomez MV; Ferreira J
Biochem Pharmacol; 2011 Feb; 81(4):544-51. PubMed ID: 21087598
[TBL] [Abstract][Full Text] [Related]
20. TRPV1 antagonists: the challenges for therapeutic targeting.
Khairatkar-Joshi N; Szallasi A
Trends Mol Med; 2009 Jan; 15(1):14-22. PubMed ID: 19097938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
